185 results about "Response to treatment" patented technology

Treatment of hypertension includes implantation of the discharge portion(s) of a catheter and/or electrical stimulation electrode(s) adjacent the tissue(s) to be stimulated. Stimulation pulses, i.e., drug infusion pulses and/or electrical pulses, are supplied by one or more implanted stimulators, through the catheter and possibly also a lead, tunneled subcutaneously between the stimulator and stimulation site. A microstimulator(s) may also/instead deliver electrical stimulation pulses. Stimulation sites include the carotid sinus and carotid body, among other locations. Treatments include drugs used for acute and/or chronic treatment of hypertension. In a number of embodiments, a need for or response to treatment is sensed, and the electrical and/or infusion pulses adjusted accordingly.

A system and method of obtaining serial biochemical, anatomical or physiological in vivo measurements of disease from one or more medical images of a patient before, during and after treatment, and measuring extent and severity of the disease is provided. First anatomical and functional image data sets are acquired, and form a first co-registered composite image data set. At least a volume of interest (ROI) within the first co-registered composite image data set is identified. The first co-registered composite image data set including the ROI is qualitatively and quantitatively analyzed to determine extent and severity of the disease. Second anatomical and functional image data sets are acquired, and form a second co-registered composite image data set. A global, rigid registration is performed on the first and second anatomical image data sets, such that the first and second functional image data sets are also globally registered. At least a ROI within the globally registered image data set using the identified ROI within the first co-registered composite image data set is identified. A local, non-rigid registration is performed on the ROI within the first co-registered composite image data set and the ROI within the globally registered image data set, thereby producing a first co-registered serial image data set. The first co-registered serial image data set including the ROIs is qualitatively and quantitatively analyzed to determine severity of the disease and/or response to treatment of the patient.

The present invention provides apparatuses and methods for creating a physiologic database or library that can be indexed to at least health, disease, patient characteristics, and acute medical crises or other dangerous condition. The present invention also provides apparatuses and methods for creating an athletic performance database or library. The database can be structured and continuous/pseudo-continuous modeling statistics applied to provide novel insight into performance and progress of an athlete or group of athletes, as well as standing relative to other athletes, or to provide novel insight into the natural history of disease and the response to treatment, and ultimately to improve care delivery.

This invention involves use of temporal or spatio/spector-temporal data (SSTD) for early classification of outputs that are results of spatio-temporal patterns of data. Classification models are based on spiking neural networks (SNN) suitable to learn and classify SSTD. The invention may predict early events in many applications, i.e. engineering, bioinformatics, neuroinformatics, predicting response to treatment of neurological and brain disease, ecology, environment, medicine, and economics, among others. The invention involves a method and system for personalized modelling of SSTD and early prediction of events based on evolving spiking neural network reservoir architecture (eSNNr). The system includes a spike-time encoding module to encode continuous value input information into spike trains, a recurrent 3D SNNr and an eSSN as an output classification module.

We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA®), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival. The two-gene classifier was also validated by qPCR in thirty AML samples from the same clinical study demonstrating a negative predictive value (NPV) and positive predictive value (PPV) of 81% and 50%, respectively (odds ratio of 4.3). These data indicate that a simple two-gene expression assay may have utility in diagnosing a population of AML patients who are more likely to respond to tipifarnib.

Methods of treating or managing specific cancers, including non-Hodgkin's lymphoma, by the administration of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Methods of using gene and protein biomarkers as a predictor of non-Hodgkin's lymphoma response to treatment with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione are also disclosed.

The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus and drug-induced lupus erythematosus by measuring cell-based complement activation products in a subject's blood. In particular, the invention describes a diagnostic method employing the measurement of multiple complement activation products, such as C3d and C4d, on the surfaces of red blood cells, white blood cells, and platelets. Kits and automated systems for performing the methods of the invention are also disclosed.

The present invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial response to treatment response with chemotherapy.

A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies.

A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.

Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to Raf kinase inhibition, are measured and identifications or adjustments may be made accordingly.

A system for identifying, monitoring and matching patients with appropriate treatments using a systemic mediator-associated physiologic test profile are provided. The system of the present invention increases the likelihood of demonstrating clinical efficacy in clinical trial datasets.

The present disclosure involves the use of metal-containing texaphyrins and zinc (II) reagents for the treatment of tumors, atheromas and other neoplastic tissue. The present application demonstrates increased oxidative stress, alterations in zinc homeostasis, cell cycle arrest, and apoptosis of cancer cells in the presence of texaphyrins and/or zinc. One aspect is to monitor oxidative stress and/or alterations in zinc homeostasis in target cells prior to and/or after treatment with metal-containing texaphyrins and/or zinc (II) reagents as a predictor for treatment efficacy. The present disclosure provides molecular basis for the cell cycle arrest and apoptosis on cancer cells in the presence of texaphyrins and zinc. Another aspect is to monitor different genes involved in response to treatment with texaphyrins and zinc prior to and/or after treatment as predictors for treatment efficacy.

Described herein are materials and methods for predicting and monitoring a heart failure patient's physiological response to treatment with a statin. More specifically, the present invention relates to the endogenous protein galectin-3 and its use as a predictor of response to treatment with 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, or statins.